TY - JOUR
T1 - Impact of population density on mortality in patients hospitalized for heart failure – JROAD-DPC Registry Analysis –
AU - Konishi, Masaaki
AU - Matsuzawa, Yasushi
AU - Ebina, Toshiaki
AU - Kosuge, Masami
AU - Gohbara, Masaomi
AU - Nishimura, Kunihiro
AU - Nakai, Michikazu
AU - Miyamoto, Yoshihiro
AU - Saito, Yoshihiko
AU - Tsutsui, Hiroyuki
AU - Komuro, Issei
AU - Ogawa, Hisao
AU - Tamura, Kouichi
AU - Kimura, Kazuo
N1 - Funding Information:
K. Nishimura’s institution has received a research grant from Philips Japan Co. Y. Saito has received lecture fees from Novartis Pharma, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical, Daiichi Sankyo, Pfizer Japan, and Boehringer Ingelheim Japan. His institution has received a research grant from Novartis Pharma, Ono Pharmaceutical, St. Jude Medical Japan, Bayer, Terumo, Daiichi Sankyo, Otsuka Pharmaceutical, Kyowa Hakko Kirin, Dainippon Sumitomo Pharma, Astellas Pharma, Takeda Pharmaceutical, Teijin Pharma, Mitsubishi Tanabe Pharma, Shionogi, Kowa Pharmaceutical, Actelion Pharmaceuticals Japan. H. Tsutsui has received speakers’ bureau/honorarium from Astellas Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, DaiichiSankyo, Mitsubishi Tanabe Pharma, Teijin Pharma, Nippon Boehringer Ingelheim, Novartis Pharma K.K, Bayer Yakuhin, and Bristol-Myers Squibb; honorarium for writing promotional material for Medical Review; research grants from Actelion Pharmaceuticals Japan; scholarship funds from Astellas Pharma and Daiichi-Sankyo. I. Komuro has received lecture fees from Daiichi-Sankyo, Takeda, Boehringer Ingelheim Japan, and Tanabe Mitsubishi. His institution has received a research grant from Daiichi-Sankyo, Takeda, Boehringer Ingelheim Japan, Otsuka Pharmaceutical, Kowa Pharmaceutical, Astellas Pharma, Bayer, Dainippon Sumitomo Pharma, and Tanabe Mitsubishi. H. Ogawa has received lecture fees from MSD and Daiichi-Sankyo. K. Tamura has received lecture fees from Daiichi-Sankyo, Mochida, Kyowa-hakko Kirin, Pfizer, Boehringer Ingelheim Japan, and Dainippon-Sumitomo. His institution has received a research grant from Daiichi-Sankyo, Takeda, Mochida, Kyowa-hakko Kirin, Pfizer, Novartis, Dainippon-Sumitomo, AstraZeneca, Ono Pharmaceutical, Tsumura, Kaneka, and Oriental Yeast. K. Kimura has received lecture fees from Astrazeneca, Toa Eiyo Ltd., MSD, Bayer, and Daiichi-Sankyo. His institution has received a research grant from MSD, Daiichi-Sankyo, Ono Pharmaceutical, Pfizer, Bayer, Takeda, Boehringer Ingelheim Japan, Tanabe Mitsubishi, and Astellas Pharma. M. Konishi, Y. Matsuzawa, T. Ebina, M. Kosuge, M. Gohbara, M. Nakai, and Y. Miyamoto declare that they have no conflict of interest.
Publisher Copyright:
© 2019 Japanese College of Cardiology
PY - 2020/4
Y1 - 2020/4
N2 - Background: There is little evidence regarding social and geographic factors in patients with heart failure (HF). We sought to investigate the association between in-hospital mortality of patients with HF and population density of the patients’ area of residence in Japan. Methods: The present study is a retrospective cohort analysis of the nationwide claim-based database, the Japanese Registry Of All cardiac and vascular Diseases-Diagnostic Procedure Combination (JROAD-DPC). We selected data of 196,286 hospitalized patients with HF (median age of 81 years and 51.8% males). Results: In-hospital mortality was 14.2%, 11.8%, and 9.5% in the lower, middle, and upper tertiles of population density, respectively. Age sub-analysis showed the largest absolute rural-urban disparity in mortality was 4.6% in the oldest subgroup (≥80 years). Multivariate analysis using mixed logistic regression model revealed that higher population density was associated with lower in-hospital mortality: multivariable-adjusted odds ratio (OR): 0.785, 95% confidence interval (CI): (0.713–0.864), p < 0.001 and 0.687, 95% CI: (0.623–0.757), p < 0.001 in the middle and upper tertiles, in comparison with the lower tertile as a reference, after adjustment for age, sex, the New York Heart Association class, comorbidities, and hospital volume. The same tendency was observed in propensity score analysis using 62,291 (in the lower vs. middle tertile) and 57,228 (in the lower vs. upper tertile) matched pairs (OR: 0.797, 95% CI: 0.725-0.877, p < 0.001 and OR: 0.695, 95% CI: 0.634–0.762, p < 0.001 in the middle and upper tertile, respectively). Conclusions: Higher population density was associated with lower in-hospital mortality in HF. More research is needed to gain insight into causality.
AB - Background: There is little evidence regarding social and geographic factors in patients with heart failure (HF). We sought to investigate the association between in-hospital mortality of patients with HF and population density of the patients’ area of residence in Japan. Methods: The present study is a retrospective cohort analysis of the nationwide claim-based database, the Japanese Registry Of All cardiac and vascular Diseases-Diagnostic Procedure Combination (JROAD-DPC). We selected data of 196,286 hospitalized patients with HF (median age of 81 years and 51.8% males). Results: In-hospital mortality was 14.2%, 11.8%, and 9.5% in the lower, middle, and upper tertiles of population density, respectively. Age sub-analysis showed the largest absolute rural-urban disparity in mortality was 4.6% in the oldest subgroup (≥80 years). Multivariate analysis using mixed logistic regression model revealed that higher population density was associated with lower in-hospital mortality: multivariable-adjusted odds ratio (OR): 0.785, 95% confidence interval (CI): (0.713–0.864), p < 0.001 and 0.687, 95% CI: (0.623–0.757), p < 0.001 in the middle and upper tertiles, in comparison with the lower tertile as a reference, after adjustment for age, sex, the New York Heart Association class, comorbidities, and hospital volume. The same tendency was observed in propensity score analysis using 62,291 (in the lower vs. middle tertile) and 57,228 (in the lower vs. upper tertile) matched pairs (OR: 0.797, 95% CI: 0.725-0.877, p < 0.001 and OR: 0.695, 95% CI: 0.634–0.762, p < 0.001 in the middle and upper tertile, respectively). Conclusions: Higher population density was associated with lower in-hospital mortality in HF. More research is needed to gain insight into causality.
UR - http://www.scopus.com/inward/record.url?scp=85073059708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073059708&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2019.09.008
DO - 10.1016/j.jjcc.2019.09.008
M3 - Article
C2 - 31606245
AN - SCOPUS:85073059708
SN - 0914-5087
VL - 75
SP - 447
EP - 453
JO - Journal of Cardiology
JF - Journal of Cardiology
IS - 4
ER -